A carregar...
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...
Na minha lista:
| Publicado no: | Clin Appl Thromb Hemost |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573709/ https://ncbi.nlm.nih.gov/pubmed/33054412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620948585 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|